BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38104429)

  • 1. Generation of induced pluripotent stem cell lines from two unrelated individuals with familial hypertrophic cardiomyopathy carrying the MYBPC3 missense c.1484G>A mutation.
    Ribeiro M; Martins S; Carvalho T; Furtado M; Sampaio Cabral J; Brito D; Carmo-Fonseca M; da Rocha ST
    Stem Cell Res; 2024 Feb; 74():103282. PubMed ID: 38104429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of induced pluripotent stem cell lines from two unrelated individuals with familial hypertrophic cardiomyopathy carrying MYBPC3 nonsense mutations.
    Ribeiro M; Jager J; Furtado M; Carvalho T; Cabral JMS; Brito D; Carmo-Fonseca M; Martins S; da Rocha ST
    Stem Cell Res; 2024 Apr; 76():103362. PubMed ID: 38417376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood derived induced pluripotent stem cells (iPSCs) from a female with familial hypertrophic cardiomyopathy.
    Ross SB; Fraser ST; Bagnall RD; Semsarian C
    Stem Cell Res; 2017 Apr; 20():76-79. PubMed ID: 28395744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of induced pluripotent stem cells from a patient with hypertrophic cardiomyopathy who carries the pathogenic myosin heavy chain 7 mutation p.Arg403Gln.
    Holliday M; Ross SB; Lim S; Mangala M; Hill A; Szappanos HC; Hool L; Semsarian C
    Stem Cell Res; 2018 Dec; 33():269-273. PubMed ID: 30508693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVIi001-A and SCVIi002-A, for modeling hypertrophic cardiomyopathy.
    Liu L; Shenoy SP; Jahng JWS; Liu Y; Knowles JW; Zhuge Y; Wu JC
    Stem Cell Res; 2021 May; 53():102279. PubMed ID: 33743363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of human induced pluripotent stem cell lines derived from four patients with a pathogenic ALPK3 variant associated with adult-onset hypertrophic cardiomyopathy (HCM).
    Cheawsamoot C; Ramchandani R; Ameen M; Arthur Ataam J; Khongphatthanayothin A; Shotelersuk V; Karakikes I
    Stem Cell Res; 2023 Dec; 73():103233. PubMed ID: 37944352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of two iPSC lines from hypertrophic cardiomyopathy patients carrying MYBPC3 and PRKAG2 variants.
    Manhas A; Jahng JWS; Vera CD; Shenoy SP; Knowles JW; Wu JC
    Stem Cell Res; 2022 May; 61():102774. PubMed ID: 35413566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
    Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
    Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of an induced pluripotent stem cell line, ICGi029-A, by reprogramming peripheral blood mononuclear cells of a patient suffering from hypertrophic cardiomyopathy and carrying a heterozygous p.N515del mutation in MYBPC3.
    Dementyeva EV; Pavlova SV; Chernyavsky AM; Zakian SM
    Stem Cell Res; 2021 May; 53():102344. PubMed ID: 33892289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An induced pluripotent stem cell line (YCMi006-A) generated from a patient with hypertrophic cardiomyopathy who carries the ACTA1 mutation p.Ile343Met.
    Kim H; Kim HJ; Oh J; Lee ST; Won D; Choi HK; Choi JR; Kim S; Kim HP; Kim SJ; Park SW; Kang SM; Lee SH
    Stem Cell Res; 2022 Aug; 63():102874. PubMed ID: 35917599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of an induced pluripotent stem cell line from a hypertrophic cardiomyopathy patient with a pathogenic myosin binding protein C (MYBPC3) p.Arg502Trp mutation.
    Holliday M; Ross SB; Lim S; Semsarian C
    Stem Cell Res; 2018 Dec; 33():56-59. PubMed ID: 30316040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of an induced pluripotent stem cell line (ZJULLi004-A) from a hypertrophic cardiomyopathy patient carrying MYBPC3/c.3764C>A mutation.
    Sun Y; Zhou J; Wang H; Wang H; Chen X; Gong T; Liang P; Jiang C
    Stem Cell Res; 2022 Oct; 64():102898. PubMed ID: 36041398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of an induced pluripotent stem cell line (SYSUi005-A) from a patient with hypertrophic cardiomyopathy.
    Zhang C; Shi J; Zhang Z; Zhao Q; Xie M; Chen Y; Xiang Q
    Stem Cell Res; 2022 Jan; 58():102626. PubMed ID: 34942479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A heterozygous MYBPC3 (c. 772+1G > A) mutant human induced pluripotent stem cell line (ZZUNEUi025-A) generated from a male patient with hypertrophic cardiomyopathy.
    Zhao X; Cao J; Li X; Liu M; Liu Y; Dong J; Zhao X
    Stem Cell Res; 2022 Apr; 60():102722. PubMed ID: 35257994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integration-free iPSC line ZZUNEUi028-A derived from a patient with hypertrophic cardiomyopathy carrying a heterozygous mutation (c. 1504 C > T) in MYBPC3 gene.
    Cheng D; Zhang S; Li X; Wang L; Dong J; Sang H
    Stem Cell Res; 2022 Aug; 63():102848. PubMed ID: 35772297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.
    Lan F; Lee AS; Liang P; Sanchez-Freire V; Nguyen PK; Wang L; Han L; Yen M; Wang Y; Sun N; Abilez OJ; Hu S; Ebert AD; Navarrete EG; Simmons CS; Wheeler M; Pruitt B; Lewis R; Yamaguchi Y; Ashley EA; Bers DM; Robbins RC; Longaker MT; Wu JC
    Cell Stem Cell; 2013 Jan; 12(1):101-13. PubMed ID: 23290139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation.
    Ribeiro M; Jager J; Furtado M; Carvalho T; Cabral JMS; Brito D; Carmo-Fonseca M; Martins S; da Rocha ST
    Hum Cell; 2024 Jul; 37(4):1205-1214. PubMed ID: 38762696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
    Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
    J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of three induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYH7 mutations.
    Cao X; Jahng JWS; Lee C; Zha Y; Wheeler MT; Sallam K; Wu JC
    Stem Cell Res; 2021 Aug; 55():102455. PubMed ID: 34352619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of human induced pluripotent stem cell lines carrying heterozygous PLN mutation from dilated cardiomyopathy patients.
    Caudal A; Mondejar-Parreño G; Vera CD; Williams DR; Shenoy SP; Liang D; Wu JC
    Stem Cell Res; 2022 Aug; 63():102855. PubMed ID: 35853412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.